Loading…
Insight Molecular Diagnostics Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -94.0% over 5Y.
today you would have $55.06▼ -94.5%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 11 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $7.50 | $2.38 | $2.50 | $6.42 | $43.40 | $47.80 | $45.00 | $27.60 | $93.00 | $141.00 | $125.00 | |
| P/S | 57.3x | 59.5x | 36.2x | 13.8x | 55.2x | 117.0x | 174.8x | — | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| INGNInogen Inc | $5.09 | — | 0.8x | — | -13.14% | $135.08M |
| HURATuHURA Biosciences, Inc. | $2.11 | — | 7.4x | — | -161.39% | $134.46M |
| INOInovio Pharmaceuticals Inc | $1.29 | — | 24.3x | — | -409.87% | $133.38M |
| BGMBGM Group Ltd. | $0.33 |
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Company description provided by Yahoo Finance.
| — |
| P/B | 6.3x | — | — | 1.0x | 1.5x | 3.9x | 6.3x | 4.6x | 21.0x | 33.2x | 21.0x | 15.2x |
| EPS | -$1.65 | -$4.66 | -$3.75 | -$13.25 | -$14.40 | -$9.20 | -$8.80 | -$8.40 | -$12.80 | -$8.40 | -$8.40 |
| Profit margin | -2688.83% | -1238.52% | -3225.04% | -1848.37% | -7609.81% | -2916.15% | -2461.51% | — | — | — | — | — |
| ROE | -113.24% | — | — | -135.73% | -212.59% | -98.28% | -89.39% | -72.72% | -460.24% | -440.04% | -113.24% | -83.85% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.2x |
| — |
| -9.27% |
| $131.2M |
| CNTBConnect Biopharma Holdings Ltd | $2.23 | — | 5.2x | — | -140.51% | $140.43M |
| LENZLENZ Therapeutics, Inc. | $4.13 | — | 0.6x | — | -59.21% | $129.77M |